CVS HEALTH Corp

CVS Healthcare & Pharma 2/10 Low Risk
2/10

CVS HEALTH Corp has $27.0B in total long-term debt with $63.7B in scheduled maturities. Approximately $4.0B (6% of maturities) is due within the next twelve months, and operating income covers interest expense 5.5x. Overall, CVS carries low refinancing risk (score 2/10).

Maturity Schedule

Year 1 $4.0B Year 2 $3.4B Year 3 $5.0B Year 4 $3.8B Year 5 $4.3B Beyond 5 $43.3B
Period Amount Due % of Total
Year 1 (0-12 months) $4.0B 6.3%
Year 2 (12-24 months) $3.4B 5.3%
Year 3 (24-36 months) $5.0B 7.9%
Year 4 (36-48 months) $3.8B 5.9%
Year 5 (48-60 months) $4.3B 6.7%
Beyond 5 Years $43.3B 68.0%
Total Scheduled Maturities $63.7B 100.0%

Key Metrics

Total Long-Term Debt
$27.0B
Near-Term (12mo)
$4.0B
Interest Coverage
5.5x
Debt/Equity
0.36
Cash Coverage
2.05x
Operating Income
$13.7B

Score Components

Component Value Weight
Near-Term Maturity Concentration 6.3% 30%
Interest Coverage Ratio 5.49x 25%
Debt-to-Equity Ratio 0.36 25%
Cash Coverage of Near-Term Debt 2.05x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-10. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Complete.